KALA Bio shares surge 42.70% premarket on $6M financing, $7M debt settlement with Oxford Finance, and new CEO David Lazar's appointment.

KALA Bio surged 42.70% in premarket trading following a $6 million private financing led by newly appointed CEO David Lazar and a $7 million debt settlement with Oxford Finance. The financing, which includes convertible preferred shares, and the settlement averted asset seizure, signaling operational stability. Oxford Finance also acquired a 16.5% stake via 1.62 million shares, reinforcing investor confidence. Lazar’s leadership and the restructuring efforts, though accompanied by dilution risks, were interpreted as strategic pivots to stabilize the company. These developments, combined with the avoidance of immediate financial distress.